Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-03-16
2008-08-12
Spector, Lorraine (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S145100, C435S070210, C435S335000, C436S548000, C530S387900
Reexamination Certificate
active
07411050
ABSTRACT:
Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4710457 (1987-12-01), Dupont et al.
patent: 4710473 (1987-12-01), Morris
patent: 4959314 (1990-09-01), Mark et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5457035 (1995-10-01), Baum et al.
patent: 5578569 (1996-11-01), Tam
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5599708 (1997-02-01), Mundy et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5670319 (1997-09-01), Goeddel et al.
patent: 5710013 (1998-01-01), Goeddel et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5767244 (1998-06-01), Goeddel et al.
patent: 5789550 (1998-08-01), Goeddel et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5843901 (1998-12-01), Roeske
patent: 5961974 (1999-10-01), Armitage et al.
patent: 5985832 (1999-11-01), Roodman et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6150090 (2000-11-01), Baltimore et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6284728 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 6562948 (2003-05-01), Anderson
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 6649164 (2003-11-01), Maraskovsky
patent: 6740522 (2004-05-01), Anderson
patent: 6838262 (2005-01-01), Anderson
patent: 7063841 (2006-06-01), Gorman et al.
patent: 7097834 (2006-08-01), Boyle
patent: 7262274 (2007-08-01), Anderson et al.
patent: 2002/0127637 (2002-09-01), Ni et al.
patent: 2002/0150989 (2002-10-01), Greene et al.
patent: 2003/0100069 (2003-05-01), Ni et al.
patent: 2003/0100488 (2003-05-01), Boyle
patent: 2003/0103978 (2003-06-01), Deshpande et al.
patent: 2003/0104485 (2003-06-01), Boyle
patent: 2003/0144480 (2003-07-01), Gorman et al.
patent: 2003/0166097 (2003-09-01), Greene et al.
patent: 2004/0023313 (2004-02-01), Boyle et al.
patent: 2004/0033535 (2004-02-01), Boyle et al.
patent: 2005/0089522 (2005-04-01), Anderson
patent: 56180/98 (1998-07-01), None
patent: 68518/98 (1998-11-01), None
patent: 71205/98 (1998-11-01), None
patent: 0514130 (1992-11-01), None
patent: 0526905 (1993-02-01), None
patent: 0727211 (1996-08-01), None
patent: 0816380 (1998-01-01), None
patent: 0873998 (1998-10-01), None
patent: 0874045 (1998-10-01), None
patent: 0911342 (1999-04-01), None
patent: 0955372 (1999-11-01), None
patent: 330400 (1999-05-01), None
patent: WO 86/00922 (1986-02-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 93/21946 (1993-11-01), None
patent: WO 95/11308 (1995-04-01), None
patent: WO 95/33051 (1995-12-01), None
patent: WO 96/28546 (1996-09-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 97/00317 (1997-01-01), None
patent: WO 97/00318 (1997-01-01), None
patent: WO 97/23614 (1997-07-01), None
patent: WO 98/07840 (1998-02-01), None
patent: WO 98/25958 (1998-06-01), None
patent: WO 98/28423 (1998-07-01), None
patent: WO 98/28424 (1998-07-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/46644 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 98/49305 (1998-11-01), None
patent: WO 98/54201 (1998-12-01), None
patent: WO 99/19468 (1999-04-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 99/53942 (1999-10-01), None
patent: WO 99/58674 (1999-11-01), None
patent: WO 99/65449 (1999-12-01), None
patent: WO 99/65495 (1999-12-01), None
patent: WO 01/03719 (2001-01-01), None
patent: WO 01/17543 (2001-03-01), None
patent: WO 01/18203 (2001-03-01), None
patent: WO 01/23549 (2001-04-01), None
patent: WO 02/15846 (2002-02-01), None
patent: WO 03/002713 (2003-09-01), None
Anderson et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,”Nature390:175-179, 1997.
Baker, Stacey J. and Reddy, E. Premkumar, “Transducers of life and death: TNF receptor superfamily and associated proteins,”Oncogene, 12(1):1-9, 1996.
Boyle v. Gorman and Mattson , Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39.
Camerini et al., “The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family,”J. Immunol. 147:3165, 1991.
Durkop et al., “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's Disease,”Cell68:421, 1992.
Embl database entry HS421358; accession No. W74421, homo sapiens cDNA clone 346544 containing alu repetitive element, Hillier et al., Jun. 1996.
Embl-est database accession No. R93478, yq16f06.rl homo sapian cDNA clone 197123 5′ sequence, Hillier et al., Aug. 1995.
Galibert et al., “The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-?B, a member of the TNFR superfamily,”J. Biol. Chem. 273(51):34120-34127, 1998.
GenEmbl database accession No. X15271, locus.HSTRGV3F, human T-cell receptor gammaV3F, Lefranc, M. P., Mar. 1991.
George et al., Current methods in sequence comparison and analysis, selected methods and applications, eds. David H. Schlesinger, Alan R. Liss, Inc., New York, pp. 124-129, 1988.
Gibbs, Jackson B. and Oliff, Allen, “Pharmaceutical research in molecular oncology,”Cell, 79:193-198, 1994.
Gray et al., “P-element-induced recombination in drosophila melanogaster: hybrid element insertion,”Genetics144(4):1601-1610, 1996.
Guise, Theresa A. and Mundy, Gregory R., “Cancer and bone,”Endocrine Reviews 19(1):18-54,1998.
Huang, Jing and Schreiber, Stuart L., “A yeast genetic system for selecting small molecule inhibitors of protein-protein interaction in nanodroplets,”Proc. Natl. Acad. Sci. USA, 94:13396-13401, 1997.
Itoh et al., “The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis,”Cell66:233, 1991.
Johnson et al., “Expression and structure of the human NGF receptor,”Cell47:545, 1986.
Kodaira et al., “Cloning and characterization of the gene encoding mouse osteoclast differentiation factor,”Gene230:121-127, 1999.
Kwon et al., “cDNA sequences of two inducible T-cell genes,”Proc. Natl. Acad. Sci. USA 86:1963, 1989.
Lacey et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,”Cell, 93:165-175, 1998.
Lynch et al, “A fluorescence polarization based Src-SH2 binding assay,”Analytical Biochemistry, 247:77-82, 1997.
Mallet et al., “Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor,”EMBO J. 9:1063, 1990.
Marra et al., The WashU-HHMI Mouse EST project, Accession No. AA170348, Feb. 16, 1997.
Nakagawa et al., “RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis,”Biochem. and Biophys. Res. Comm. 253:395-400, 1998.
Pullen et al., “CD40—tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding site and TRAF hetero-oligomerization,”Biochemistry37(34):11836-11845, 1998.
Roodman, G. Davi
Ausenhus Scott L.
Immunex Corporation
Spector Lorraine
Stoica Elly-Gerald
LandOfFree
Monoclonal blocking antibody to human RANKL does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal blocking antibody to human RANKL, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal blocking antibody to human RANKL will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4009641